Suven Life Sciences, a biopharmaceutical company, announces today that its drug discovery portfolio which has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators resulted in the grant of one product patent from USA (8735423) and one product patent from South Korea (10-1410903). The patents are corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

With these new patents, Suven has a total of nineteen granted patents from USA and fifteen granted patents from South Korea. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for Major Depressive Disorder (MDD) with high unmet medical need with huge market potential globally'' says Venkat Jasti, CEO of Suven.

Shares of the company gained Rs 9, or 4.93%, to trade at Rs 191.60. The total volume of shares traded was 249,466 at the BSE (10.51 a.m., Monday).